Century Therapeutics, Inc.

NasdaqCM:IPSC Stock Report

Market Cap: US$405.8m

Century Therapeutics Management

Management criteria checks 2/4

Century Therapeutics' CEO is Brent Pfeiffenberger, appointed in Dec 2023, has a tenure of 2.5 years. total yearly compensation is $3.06M, comprised of 20.9% salary and 79.1% bonuses, including company stock and options. directly owns 2.04% of the company’s shares, worth $8.28M. The average tenure of the management team and the board of directors is 1.3 years and 3.8 years respectively.

Key information

Brent Pfeiffenberger

Chief executive officer

US$3.1m

Total compensation

CEO salary percentage20.91%
CEO tenure2.5yrs
CEO ownership2.0%
Management average tenure1.3yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

Analysis Article • Dec 17

There's No Escaping Century Therapeutics, Inc.'s (NASDAQ:IPSC) Muted Revenues Despite A 32% Share Price Rise

Century Therapeutics, Inc. ( NASDAQ:IPSC ) shareholders have had their patience rewarded with a 32% share price jump in...
Analysis Article • Nov 30

We're Keeping An Eye On Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Oct 08

There Is A Reason Century Therapeutics, Inc.'s (NASDAQ:IPSC) Price Is Undemanding

Century Therapeutics, Inc.'s ( NASDAQ:IPSC ) price-to-sales (or "P/S") ratio of 0.4x might make it look like a strong...
Seeking Alpha • Jun 20

Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101

Summary Positive poster presentation results were released at ASCO 2024 from the phase 1 ELiPSE-1 study, which used CNTY-101 for the treatment of patients with relapsed/refractory CD19-positive non-Hodgkin lymphoma patients. The global non-Hodgkin Lymphoma market is expected to surge to $11 billion by 2029. Initiation of phase 1 CALiPSO-1 study, using CNTY-101 for patients with systemic lupus erythematosus, is expected in the 1st half of 2024; Data from this study is to be released 2nd half of 2024. A highly important thing about this company would be the Allo-Evasion technology incorporated into the iPSC-derived cell therapies, which not only improves the safety of patients but could mean improved responses. Read the full article on Seeking Alpha
Analysis Article • Mar 06

Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Feb 01

Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy

Summary Century Therapeutics is a biotech focused on developing engineered natural killer cells for cancer and rheumatologic conditions. Their first clinical product, CNTY-101, showed promising early data with a patient experiencing tumor shrinkage and a complete clinical response. However, Century Therapeutics has a limited cash position and needs to prove the efficacy of their therapies before being considered a confident investment. Read the full article on Seeking Alpha
Analysis Article • Oct 23

We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Aug 25

Century Therapeutics receives IND clearance for allogeneic cell therapy candidate

Century Therapeutics (NASDAQ:IPSC) will begin a phase 1 study of its allogeneic cell therapy CNTY-101 by the end of the year after receiving Investigational New Drug clearance from the US FDA. CNTY-101 is under investigation for relapsed or refractory CD19 positive B-cell malignancies. In the ELiPSE-1 study, all patients will receive an initial standard dose of conditioning chemotherapy. Schedule A consists of a single-dose escalation of CNTY-101 and subcutaneous IL-2. Schedule B will evaluate a three-dose schedule per cycle of CNTY-101. CNTY-101 is derived from a clonal  induced pluripotent stem cell (iPSC) master cell bank that yields homogeneous product. Seeking Alpha's Quant Rating views Century (IPSC) as a hold with strong grades for profitability and momentum.

CEO Compensation Analysis

How has Brent Pfeiffenberger's remuneration changed compared to Century Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$108m

Dec 31 2025US$3mUS$641k

-US$10m

Sep 30 2025n/an/a

-US$26m

Jun 30 2025n/an/a

-US$23m

Mar 31 2025n/an/a

-US$22m

Dec 31 2024US$2mUS$625k

-US$127m

Sep 30 2024n/an/a

-US$130m

Jun 30 2024n/an/a

-US$131m

Mar 31 2024n/an/a

-US$133m

Dec 31 2023US$3mUS$50k

-US$137m

Compensation vs Market: Brent's total compensation ($USD3.06M) is about average for companies of similar size in the US market ($USD2.48M).

Compensation vs Earnings: Brent's compensation has increased whilst the company is unprofitable.

CEO

Brent Pfeiffenberger (48 yo)

2.5yrs
Tenure
US$3,064,022
Compensation

Dr. Brent Pfeiffenberger, Pharm D., MBA, has been Chief Executive Officer, President and Director of Century Therapeutics, Inc. since December 04, 2023 and serves as its Chairman since August 14, 2025. He...

Leadership Team

NamePositionTenureCompensationOwnership
Brent Pfeiffenberger
President2.5yrsUS$3.06m2.04%
$ 8.3m
Gregory Russotti
Chief Technology & Manufacturing Officer2.5yrsUS$912.32k0.34%
$ 1.4m
Chad Cowan
Chief Scientific Officer1.7yrsUS$1.17m0.13%
$ 512.4k
Douglas Carr
Senior VP of Finance & Operationsless than a yearno data0.28%
$ 1.1m
Krista Kauppinen
VP, General Counsel & Head of Intellectual Propertyless than a yearno datano data
Megan Bilson
Chief People Officerless than a yearno datano data
Michael Naso
Senior VP of Cell Engineering3.1yrsno datano data
Elizabeth Devlin
VP & Head of Developmentless than a yearno datano data
1.3yrs
Average Tenure
54yo
Average Age

Experienced Management: IPSC's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Brent Pfeiffenberger
President2.5yrsUS$3.06m2.04%
$ 8.3m
Joseph Jimenez
Special Advisor to the Boardno dataUS$69.93k0.27%
$ 1.1m
Martin Murphy
Independent Directorless than a yearUS$40.34kno data
Timothy Walbert
Independent Director3.8yrsUS$63.05k0%
$ 0
Alessandro Riva
Independent Director5.1yrsUS$67.43k0%
$ 0
Daphne Quimi
Independent Director3.8yrsUS$77.05k0.0028%
$ 11.2k
Kimberly Blackwell
Lead Independent Director5.1yrsUS$71.05k0%
$ 0
Han Lee
Independent Directorless than a yearUS$40.24kno data
3.8yrs
Average Tenure
58.5yo
Average Age

Experienced Board: IPSC's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/14 23:45
End of Day Share Price 2026/06/12 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Century Therapeutics, Inc. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBofA Global Research
Chen YangBofA Global Research
William MaughanCanaccord Genuity